Vaccine Acceleration by Modular Progression, or VAMP

The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability.



The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical’s Vaccine Acceleration by Modular Progression (VAMP) is a nucleic acid vaccine development platform that facilitates rapid delivery of safe and effective nucleic acid based vaccines to the warfighter or the general population. VAMP relies on a modular contracting strategy to fund development of multiple mRNA vaccine candidates simultaneously, delivering mRNA vaccines against new and emerging biological threats to enhance overall preparedness.

Typical Vaccine Development Platform, one contract at a time, against one threat
VAMP Vaccine Development Platform
Modular Contracting Strategy:
GO/NO GO checkpoints through initial Phase I development to decrease risk and maximize  success of mRNA vaccine candidate. Multiple simultaneous mRNA vaccine contracts against different threat families; Partnership with industry that has proven mRNA or nucleic acid vaccine technology.
VAMP Vaccine Development Platform
Learn more about VAMP in the article "COVID-19 Lessons Learned Pave the Way for Future Successful Emergency-Use Vaccines." VAMP vials and syringes

"Thanks to our partnerships and a broad scientific understanding of other coronaviruses, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the U.S. government and private industry partners were able to quickly develop a safe and effective COVID-19 vaccine. The success of the COVID-19 vaccine has shown us that investment in mRNA vaccines will enable us to develop a framework and strategic reserves to cover broader threat families in a more expeditious fashion."

Colonel Ryan Eckmeier
Joint Project Manager for the Chemical, Biological, Radiological, and Nuclear Medical Joint Project Management Office